Recently, albumin-bound paclitaxel for injection, an oncology product introduced by Kexing Biopharm in collaboration with Haichang Biotech, has received marketing authorization from Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT). This marks another key breakthrough in Kexing Biopharm's internationalization strategy in Latin America.
Cancer remains a major public health concern in Argentina. Data from the International Agency for Research on Cancer (IARC) show that the country has relatively high cancer incidence and mortality rates. Breast cancer is the most common and deadliest cancer among women, while prostate cancer and lung cancer represent the most significant threats to men. These factors underscore the clinical need for safer and more effective oncology treatments.
Paclitaxel for Injection (Albumin-Bound) is a widely recognized, broad-spectrum anticancer therapy indicated for metastatic breast cancer, non-small cell lung cancer, and metastatic pancreatic cancer. Compared with conventional paclitaxel formulations, it offers improved safety, tolerability, and patient compliance, and has gained broad clinical acceptance. The approval in Argentina is expected to better address local clinical needs and provide patients with greater access to high-quality treatment options.
Notably, the product was approved in the European Union in 2024, and the EU’s stringent regulatory endorsement has significantly accelerated its global commercialization. Since then, it has obtained marketing approvals in multiple countries, including Peru, Oman, Uruguay, and Georgia, further strengthening its presence in Latin America and other emerging markets.
Looking ahead, Kexing Biopharm plans to leverage Argentina as a strategic hub to expand its footprint across Latin America. The company will continue to advance international registrations and commercialization of high-quality innovative medicines, contributing to improved healthcare outcomes for patients worldwide.
Kexing Biopharm (SSE: 688136) is an innovative, international biopharmaceutical company integrating R&D, manufacturing, and commercialization. The company focuses on recombinant proteins, multifunctional antibodies, and targeted drug delivery technologies, with therapeutic strengths in oncology, autoimmune diseases, and antiviral treatments. Driven by a dual strategy of innovation and globalization, Kexing Biopharm is committed to becoming a leading provider of high-quality biologics and serving patients across global markets.
https://www.kexingbiopharm.com/
Kexing Biopharm
About Author
